Vildan KAYA, Aylin Fidan KORCUM, Mustafa YILDIRIM, Melek Gamze AKSU, Hasan MUTLU, Beyza Şirin ÖZDEMİR, Ali Aydın YAVUZ

Adjuvan Kemoradyoterapi Uygulanan Mide Kanserli Hastalarda Prognostik Faktörler

Amaç: Mide kanseri progresif seyirli bir hastalıktır. Tek küratif tedavi olan cerrahiye rağmen hastalık nüks edebilmektedir. Çalışmamızda mide kanseri nedeniyle adjuvan kemoradyoterapi uyguladığımız hastalarda klinikopatolojik prognostik faktörler araştırıldı. Materyal ve Metod: Tıp Fakültesi Radyasyon Onkolojisi Anabilim Dalında 2008-2011 yılları arasında postoperatif 5FU bazlı kemoterapi ve eş zamanlı radyoterapi uygulanan hastaların verileri incelendi. Bulgular: Çalışmaya 25’i %31.6 kadın, 54’ü erkek %68.4 toplam 79 hasta alındı. Hastaların ortalama takip süreleri 21.5±14.1 3.8- 87.6 aydı. Hastaların 2 yıllık sağkalımı %63.8, 3 yıllık sağkalımı %39.3 olarak saptandı. Genel sağkalımın çok değişkenli analizlerle incelenmesinde cinsiyet, yaş, tümör invazyon derinliği, histolojik grade ve histolojik alt tipi ile sağkalım arasında ilişki tespit edilmedi p=0.358, p=0.156, p=0.223, p=0.939 . Buna karşın hastaların lenf nodu durumu ve hastalığın evresi ile genel sağkalım arasında istatiksel anlamlılık saptandı p=0.002, p=0.003 . Tartışma: Çalışmamızda literatürle uyumlu olarak evre ve lenf nodu durumunun hem hastalıksız sağkalım hem de genel sağkalım için en önemli prognostik faktörler olduğunu ortaya koyduk.

Prognostic Factors In Gastric Cancer Patients Treated With Adjuvant Chemoradiotherapy

Aim: Gastric cancer is a progressive disease. Although surgery is the only curative treatment, recurrence can occur. In our study, clinicopathologic prognostic factors are investigated in gastric cancer patients who underwent adjuvant chemoradiotherapy.Material and Method: The patients that underwent postoperative 5-FU based chemotherapy and concurrent radiotherapy between the years of 2008-2011 in Medical School, have been examined. Results: In this study, 25 female 31.6% and 54 male patients 68.4% from a total of 79 patients are included. The main follow-up period was 21.5±14.1 3.8- 87.6 months. Patients 2-year survival and 3-year survival rate was found as 63.8% and 39.3%, respectively. In research of overall survival with multivariate analyses, no relationship was established between survival and gender, age, depth of tumor invasion, histological grade and histological subtype p=0.358, p=0.156, p=0.223, p=0.939 . In contrast, statistical significance was found between overall survival and lymph node status of patients and stage of disease p=0.002, p=0.003 .Conclusions: In our study, which is consistent with literature, it was revealed that the stage of disease and lymph node status are the most important prognostic factors for both disease free survival and overall survival

Keywords:

gastric cancer, chemoradiotherapy, prognosis, stage, lymph node,

PDF

___

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.

Rajdev L. Treatment options for surgically resectable gastric cancer. Curr Treat Options Oncol 2010;11:14-23.

Bouché O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005;16:1488-97.

Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med 2001;345:725-30.

Min C, Bangalore S, Jhawar S, et al. Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: a meta-analysis of randomized trials. Oncology 2014;86:79-85.

Sakuramoto S, Yamashita K, Watanabe M. Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World J Gastrointest Oncol 2009;1:47-54.

Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol 2014;6:393-402.

Macdonald JS. Role of post-operative chemoradiation in resected gastric cancer. J Surg Oncol 2005;90:166-70.

Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-33.

Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T; Southwest Oncology Group and the Gastric Intergroup. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 2002:9(3):278-86.

Costa WL Jr, Coimbra FJ, Fogaroli RC, et al. Adjuvant chemoradiotherapy after D2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center. Radiat Oncol 2012;7:169.

Lim do H. Postoperative adjuvant radiotherapy for patients with gastric adenocarcinoma. J Gastric Cancer 2012;4:205-9.

Soyfer V, Geva R, Michelson M, Inbar M, Shacham-Shmueli E, Corn BW. The impact of overall radiotherapy treatment time and delay in initiation of radiotherapy on local control and distant metastases in gastric cancer. Radiat Oncol 2014;9:81.

Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279-85.

Zárate RN, Arias F, Bandres E, Cubedo E, Malumbres R, García- Foncillas J. Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo- radiotherapy. World J Gastroenterol 2006;12:6032-6.